---
title: "Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279996465.md"
datetime: "2026-03-20T21:42:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279996465.md)
  - [en](https://longbridge.com/en/news/279996465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279996465.md)
---

# Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing

March 20 (Reuters) - SEC Filing: \* SPRUCE BIOSCIENCES INC - ON MARCH 16, ENTERED TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL - SEC FILING \* SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING \* SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES Source text: Further company coverage: (SPRB.O)

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SPRB.US](https://longbridge.com/en/quote/SPRB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | SPRB Stock News](https://longbridge.com/en/news/286256216.md)
- [Spruce Biosciences Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/286257998.md)
- [Liquidia Q1 EPS beats estimates as YUTREPIA sales drive profit](https://longbridge.com/en/news/285925039.md)
- [<![CDATA[FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma]]>](https://longbridge.com/en/news/285959741.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)